Characterization of placenta-derived mesenchymal stem cells cultured in autologous human cord blood serum

Abstract

Human placenta-derived mesenchymal stem cells (P-MSCs) have drawn increasing attention in the field of stem cell research due to their potential in clinical applications as well as their rich and easy to procure cell source. While studies demonstrating the potential of P-MSCs for therapeutic transplantations have been documented, a clinically compliant procedure for P-MSC expansion in vitro has yet to be established. To this end, previous studies have demonstrated that MSCs of bone marrow and cord blood origins cultured in human cord blood serum (hCBS) are comparable to those cultured in fetal bovine serum (FBS), indicating that hCBS may be an alternative to FBS for the development of in vitro cell expansion procedures free of animal components. However, stem cells from origins other than bone marrow or cord blood, particularly from human placental tissues, which have demonstrated a good potential for clinical applications, have not been characterized under similar conditions. In this study, in an attempt to define a clinically compliant protocol for P-MSC expansion in vitro, we examined the effects of human hCBS as a replacement for FBS on cell proliferation capacity, differentiation potential, MSC-specific phenotypic expression and the genetic stability of P-MSCs in cultures. P-MSCs expanded in vitro in autologous hCBS maintained the capacity of self‑renewal and expressed surface antigens characteristic of bone marrow-derived mesenchymal stem cells. Under differentiation conditions, the P-MSCs expanded in hCBS developed into adipogenic, osteogenic and neurogenic cell phenotypes. Chromosomal karyotyping and single cell gel electrophoresis analysis demonstrated that P-MSCs cultured in autologous hCBS were genetically stable. These results suggest that autologous hCBS may be used as an alternative to FBS for the in vitro expansion of P-MSCs for clinical applications.

Placental mesenchymal stem cells of fetal and maternal origins demonstrate different therapeutic potentials

“…The Human Research Ethics Committee at Ningxia Medical University approved this study. Fetal and maternal P-MSCs were isolated and genetic origin verified as described previously [18]. The cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine and 50 μg/ml gentamycin (Invitrogen, Carlsbad, CA, USA).…”

“…A human placenta contains MSCs of both fetal and maternal origin. We [18] and others [13,19,20] have previously isolated and characterized fetal and maternal MSCs from human placentas. Compared with placental MSCs (P-MSCs) of maternal origins, fetal MSCs have demonstrated stronger immunomodulatory function and higher osteogenic differentiation potential [13,20].…”

Impaired Angiogenic Potential of Human Placental Mesenchymal Stromal Cells in Intrauterine Growth Restriction

“…Cells derived from PM showed the XY phenotype (spectrum green and orange-labeled chromosomes, respectively) and were therefore 100% male (Fig. 1E, 1F) as previously described [34]. Two spectrum green-labeled X chromosomes were visible in cells derived from PBD with a low contamination (,5%) of XY phenotype; therefore, these cells were prevalently of maternal origin (Fig.…”

Testicular tissue cryopreservation and spermatogonial stem cell transplantation to restore fertility: from bench to bedside

“…Alterations in manipulated cells may occur in the genome, in the epigenome, or in both [63-65]. There are reports that show the genetic stability of other stem cell populations during in vitro culture [66,67]. Since SSCs are the cells that transmit genetic information to the next generations, concerns about SSC stability are much more important than those about somatic cells.…”